Value & Access
Decision-makers decide on access to innovations, yielding better patient outcomes and value to healthcare systems and society, whilst considering resources and financial sustainability. The EU HTA Regulation, Project ORBIS, DARWIN EU and cross-country HTA collaborations show stakeholders’ willingness to achieve these aims. This track will discuss the role and ways of working of all stakeholders to improve assessment and decision-making sustainability in the European access environment
Who is This Track Designed For?
Value demonstration and patient access is relevant across different stakeholders. This track is designed for clinical, regulatory, patient, and value and market access experts who are interested in the link between technology innovators, regulatory, HTA and local decision-making, and how collaboration and engagement can improve patient access. We invite abstracts containing multifunctional/multistakeholder perspectives (at a minimum Regulatory and Access perspectives) and gender balance is encouraged.
Patient Safety Medical Device Lead
Astrazeneca, United Kingdom
Senior Principal, EMEA Value & Payer Evidence
IQVIA, United Kingdom
Senior Technical Advisor
Management Sciences for Health, Ukraine
DIA Europe 2023 Highlights
It will provide updates on key developments on the GCP Renovation (ICH E6, ICH E8), Clinical Trial Regulation, the Clinical Trial Information System, data submission, transparency, navigating ethical approval, study design in the digital age, innovative clinical trial designs (umbrella and platform trials, patient centricity), digital tools in development and other hot topics. It should be a must-attend for optimising development programmes and identifying cost savings through efficiency and innovation.